Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: $MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mirum Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mirum Pharmaceuticals's position in the market.
Mirum Pharmaceuticals reported a strong first quarter in 2024, with total revenue of $69.2 million and on track to achieve full-year guidance of $310 to $320 million. The FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients was achieved in March. The company maintains a cash balance of $302.8 million as of March 31, 2024, and has important interim analyses scheduled for June 2024. Mirum's commercial business is performing well, with continued demand growth and net sales increase.
Mirum Pharmaceuticals, a biopharmaceutical company specializing in rare and orphan diseases, is set to present at the Citizens JMP Life Sciences Conference in New York on May 14th. Investors can access the webcast via Mirum's website.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced the publication of Phase 3 MARCH data in The Lancet, showcasing the benefits of LIVMARLI (maralixibat) in patients with PFIC. The study confirmed the efficacy and safety of LIVMARLI across a broad genetic range of PFIC types, with significant improvements observed in pruritus, serum bile acids, growth, and bilirubin levels.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will announce its first quarter 2024 financial results on May 8, 2024, followed by a conference call to discuss recent corporate progress. The call will be accessible via phone or webcast.
